900789-14-2

Basic information

• Product Name: 5-BroMo-2,4-dichloro-7H-pyrrolo[2,3-d]pyriMidine
• Synonyms: 5-BroMo-2,4-dichloro-7H-pyrrolo[2,3-d]pyriMidine
• CAS NO: 900789-14-2
• Molecular Formula: C₆H₂BrCl₂N₃
• Molecular Weight: 266.91018
• Mol File: 900789-14-2.mol
• Article Data: 4

Chemical Properties

• Melting Point: 226 °C(Solv: dichloromethane (75-09-2))
• Appearance: /
• Density: 2.079g/cm³
• Refractive Index: 1.748
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 8.61±0.50(Predicted)
• CAS DataBase Reference: 5-BroMo-2,4-dichloro-7H-pyrrolo[2,3-d]pyriMidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BroMo-2,4-dichloro-7H-pyrrolo[2,3-d]pyriMidine(900789-14-2)
• EPA Substance Registry System: 5-BroMo-2,4-dichloro-7H-pyrrolo[2,3-d]pyriMidine(900789-14-2)

Safety Data

• Hazardous Substances Data: 900789-14-2(Hazardous Substances Data)

Usage

General Description

5-Bromo-2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine is a chemical compound with the molecular formula C6H2BrCl2N3. It is a heterocyclic organic compound with a pyrrolopyrimidine structure, which is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. 5-Bromo-2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine is known for its potent inhibitory activity against certain enzymes and has been studied for its potential uses in the development of new drugs. Additionally, it is also used as a precursor in the synthesis of various biologically active compounds. Due to its versatile reactivity and potential applications in drug discovery and development, 5-Bromo-2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine is an important compound in the field of organic chemistry and medicinal chemistry.

InChI:InChI=1/C6H2BrCl2N3/c7-2-1-10-5-3(2)4(8)11-6(9)12-5/h1H,(H,10,11,12)

Upstream product

• 90213-66-4 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 1053228-32-2 5-bromo-2,4-dichloro-7-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine 
• 1060815-86-2 2,4-dichloro-5-methyl-7H-pyrrolo[2,3-d]pyrimidine 

Relevant articles and documents

Synthetic method of 5-bromo-2-chloro-7H-pyrrolo[2,3-d]pyrimidine

The invention provides a synthetic method of 5-bromo-2-chloro-7H-pyrrolo[2,3-d]pyrimidine. 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine is dissolved in tetrahydrofuran, N-bromsucciniamide is added at theroom temperature, and stirring is conducted for 1-2 h; filtering, washing and ethanol recrystallization are conducted to obtain the pure 5-bromo-2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine is obtained; the pure 5-bromo-2,4-dichloro -7H-pyrrolo[2,3-d]pyrimidine, zinc powder and acetic acid are mixed, a heating reflux reaction is conducted, filtering is conducted, ethyl alcohol is removed by steaming,dissolving is conducted through an organic solvent, washing is conducted through a saturated sodium bicarbonate aqueous solution, washing is conducted through saturated salt, drying is conducted, drying by distillation is conducted, and a coarse product is obtained; and a pure product is obtained from the coarse product through ethane recrystallization. According to the synthetic method of the 5-bromo-2-chloro-7H-pyrrolo[2,3-d]pyrimidine, commercially-available raw materials are subjected to bromination and reduction reaction to generate the pure product; the raw materials are supplied commercially in large amount, are cheap and easy to obtain, auxiliary materials can be recycled and reused, the cost is obviously lowered, meanwhile pollution of toxic substances to the environment in the production process is avoided, and the safety in the operation process is improved; and the yield is greatly increased, the time is effectively shortened, operation is easy, and the post-processing process is simplified.

INHIBITORS OF PROTEIN KINASES

The present invention is directed to compounds of formula (I)-(II) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.